AG真人官方

Bank of Montreal and affiliates have filed Amendment No. 1 to Schedule 13G on Translational Development Acquisition Corp. (Class A Ordinary Shares, CUSIP G9008W105). As of 30 Jun 2025 the group beneficially owns 800,000 shares, representing 4.64 % of the outstanding class. All voting and dispositive powers are shared among Bank of Montreal, Bank of Montreal Holding Inc., and BMO Nesbitt Burns Inc.; none have sole power. The stake is held in the ordinary course of business while acting as prime broker for clients, and the filers state the holdings were not acquired to influence control of the issuer. Because ownership is now below the 5 % threshold (Item 5), the filing reflects a position under the level that triggers more extensive disclosure. No other material transactions, earnings data, or control intentions are disclosed.

On 30 Jul 2025, S&T Bancorp, Inc. (NASDAQ: STBA) filed an Form 8-K announcing the Board鈥檚 approval of a $0.34 quarterly cash dividend. The payout is $0.01 higher than the same period last year, representing a 3.03 % increase. Using the 29 Jul 2025 closing share price of $37.63, the new dividend equates to an annualized yield of 3.61 %. The dividend is payable on 28 Aug 2025 to shareholders of record as of 14 Aug 2025. Aside from attaching the related press release (Exhibit 99.1), the filing contains no additional financial results or strategic actions.

Salesforce, Inc. (CRM) 鈥� Form 4 filed 07/30/2025

Chair & CEO Marc Benioff exercised 2,250 non-qualified stock options at an exercise price of $161.50 and immediately sold the same 2,250 shares under a Rule 10b5-1 plan on 07/29/2025. Shares were sold in six tranches between $267.46-$273.51, generating roughly $0.6 million in gross proceeds. Post-transaction direct ownership is 11,911,571 shares, down only 0.02%; indirect holdings remain 107,000 shares in trust and 10,000,000 shares via Marc Benioff Fund LLC. The option exercise reduces his remaining option balance to 150,872. Given the minuscule percentage change and pre-scheduled nature, the filing appears routine and does not materially impact insider ownership or signal a strategic shift.

Gabelli-affiliated investment vehicles filed a Schedule 13D on 28 Jul 2025 disclosing ownership of 251,650 Series A shares of DallasNews Corp. (DALN), representing 5.31 % of the 4.74 million shares outstanding.

• Gabelli Funds: 105,350 sh (2.22%)
• Gabelli & Co Investment Advisers (GCIA): 90,800 sh (1.92%)
• GAMCO Asset Management: 45,000 sh (0.95%)
• Teton Advisors: 10,500 sh (0.22%)

The group spent approximately $3.06 million accumulating shares between 8 Jul 鈥� 24 Jul 2025 at prices ranging $4.50 to $16.01, funded largely through client accounts. Although reported on a 13D (non-passive) basis, the filing states the investors do not currently seek control of DALN; future buying or selling will depend on ongoing analysis of the company鈥檚 operations, valuation and market conditions.

The investors outline typical value-oriented governance preferences (support for cumulative voting, opposition to poison pills, etc.) and note that voting power above 25% would be delegated to independent committees. Their presence introduces an experienced shareholder that may influence strategic dialogue, but immediate operational changes are not signalled.

Entera Bio (ENTX) filed an 8-K to disclose a favourable FDA response that de-risks the clinical path of its lead osteoporosis candidate, EB613. In a written Type A meeting reply dated 28 Jul 2025, the FDA agreed that a single 24-month, multinational, randomized, double-blind, placebo-controlled Phase 3 study in post-menopausal women鈥攗sing change in total-hip Bone Mineral Density (BMD) as the primary endpoint and vertebral-fracture incidence as the key secondary endpoint鈥攚ill be sufficient to support a future New Drug Application.

The agency also previously waived requirements for dedicated oral carcinogenicity studies (14 May 2025) and comprehensive DART studies (12 Jun 2025) based on existing Forteo data, literature, and EB613鈥檚 own non-clinical package. Collectively, these decisions shorten development timelines, reduce cost, and clarify the registrational strategy. No financial metrics were provided, and the information was furnished under Reg FD (Items 7.01/8.01), meaning it is not deemed filed for liability purposes.

Telomir Pharmaceuticals (NASDAQ: TELO) filed an 8-K disclosing that on 18 July 2025 it sold 1,100,000 common shares through its at-the-market facility at an average price of $2.6045, a premium to the prior day鈥檚 close. The block trades were placed with institutional investors and executed by Rodman & Renshaw on the StockBlock platform. Gross proceeds totalled 鈮�$2.9 million before fees; no warrants or other equity sweeteners were issued.

The transaction immediately increases cash while modestly diluting existing shareholders via the new share issuance. Because the raise was completed at a premium and without warrant overhang, the near-term balance-sheet impact is positive, though future EPS will be spread over a larger share count.

Covista Capital Corp., a British Columbia鈥揵ased investment fund manager, filed Amendment No. 2 to Schedule 13G on 11 July 2025 disclosing its ownership in DallasNews Corp. (DALN) Series A common stock.

• Shares held: 235,000
• Ownership percentage: 4.96 % of the outstanding Series A common
• Voting & dispositive power: Sole voting and sole dispositive power over the entire position; no shared power reported
• Filing status: Passive institutional holder under Rule 13d-1(b); filer is classified as an Investment Adviser
• Threshold note: The stake is just below the 5 % level that would otherwise trigger Schedule 13D obligations

No other entities or subsidiaries are part of a group, and the filer certifies that the Canadian regulatory regime is substantially comparable to U.S. standards. The certification is signed by CIO Rann Cannon on 15 July 2025.